H.C. Wainwright assumed coverage of Can-Fite BioPharma (CANF) with a Buy rating and $2.50 price target The firm says the company has two late-stage oral selective A3 adenosine receptor agonists, that are being developed as therapies for psoriasis and liver cancer, respectively. It believes A3AR agonists are novel and can selectively target pathogenic cells.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma Reschedules Shareholder Meeting Due to Lack of Quorum
- Can-Fite BioPharma’s Phase 3 Psoriasis Study: A Potential Game Changer?
- Can-Fite BioPharma’s Promising Phase 3 Trial for Liver Cancer Treatment
- Can-Fite BioPharma’s Promising Phase 2 Study on Namodenoson for Pancreatic Cancer
- Can-Fite BioPharma Announces Special Shareholder Meeting for Capital Restructuring